Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

Gadolinium-enhanced cardiac magnetic res

Gadolinium-enhanced cardiac magnetic resonance imaging: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines

✍ Marcelo Nacif; Andrew E Arai; Joao A Lima; David A Bluemke 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 98 KB

The Food and Drug Administration (FDA) has recently recommended that the label dose of Gadolinium (Gd)based contrast agents (GBCA) not be exceeded. The primary concern for high dose GBCAs application is nephrogenic systemic fibrosis (NSF). For the majority of conventional GBCA, the label dose is 0.1